Nemaura Pharma Limited

[Not Yet Scheduled]
With over 100 patents across over 20 patent families, and 5 transdermal patches in active development and over 20 injectable formulations in novel delivery devices, Nemaura Pharma is aiming to lead the global markets in the field of drug delivery through the skin.

Nemaura was awarded the Frost and Sullivan Business Leadership award for Europe in 2016 for its novel advanced skin drug delivery platform and won the UK national award for Drug Delivery systems for its solid dose vaccine delivery platform.

Situated in central England, the company possesses its own R&D labs, formation labs, medical device development and prototyping facility and GMP IMP suite for aseptic drug and transdermal patch manufacture.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
Not Provided
Company HQ Country:
United Kingdom
Year Founded:
2005
Main Therapeutic Focus:
Lead Product in Development:
Teriparatide and Rivastigmine
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
photo
CEO
Nemaura Pharma Limited